Aspivix closes $2M investment series
20.08.2018
Lausanne-based medtech Aspivix has secured over CHF 1.8M in a series A financing round. The newly acquired funds will accelerate product development and clinical research, and support scaling up production for the European market.
 Mathieu Horras, CEO and co-founder of Aspivix SA. © Alain Herzog
|
 |
Aspivix develops non-traumatic, minimally invasive surgical instruments for gynaecology. Its first product is dedicated to allowing painless placement of intra-uterine contraceptive devices and other gynaecology procedures. Current procedures use forceps, causing pain and frequent bleeding. Aspivix’s device is a simple, patented, single-use medical instrument that reduces pain, eliminates the risk of lesions and bleeding, avoids the risk of cross-contamination, and streamlines the procedure significantly.
The financing round was led by venture capital firm 4FO, with co-investment from ZKB and business angels BAS. Aspivix will use the proceeds to finalize the development and support the clinical trial of its product, boost its industrialization process and bring it to the European market.
The startup passed Venture Kick stage 2 in May 2018.“From the very beginning, our philosophy was to build a strong team and a smart product. Venture Kick, through the very first financial support, provided a significant validation of both. Besides, the feedback received in bootcamps and from various juries became instrumental in shaping and communicating our business vision,” says Mathieu Horras, CEO and co-founder of Aspivix SA.
The financing round was led by venture capital firm 4FO, with co-investment from ZKB and business angels BAS. Aspivix will use the proceeds to finalize the development and support the clinical trial of its product, boost its industrialization process and bring it to the European market.
The startup passed Venture Kick stage 2 in May 2018.“From the very beginning, our philosophy was to build a strong team and a smart product. Venture Kick, through the very first financial support, provided a significant validation of both. Besides, the feedback received in bootcamps and from various juries became instrumental in shaping and communicating our business vision,” says Mathieu Horras, CEO and co-founder of Aspivix SA.